Identification and experimental validation of biomarkers associated with lipotoxicity in chronic obstructive pulmonary disease through transcriptomic and single-cell RNA sequencing analysis

Chronic obstructive pulmonary disease, commonly known as COPD, is a long-term condition that makes breathing difficult. It damages the airways and the tiny air sacs in the lungs, often caused by smoking or exposure to harmful air. While doctors can treat the symptoms, the disease itself cannot be reversed, and finding new ways to stop it from getting worse remains a major challenge for medical science. One area of growing interest is how the body handles fats. Just as too much sugar can harm the body, an imbalance in how fats are stored and used can lead to a state called lipotoxicity. This condition occurs when fat builds up in places it shouldn't, triggering inflammation and damaging cells. Researchers have long suspected that this fat-related damage plays a hidden role in lung diseases, but the precise involvement of lipotoxicity-related genes in COPD remains unclear.

A team of scientists at Shanxi Bethune Hospital and Shanxi Medical University set out to solve this puzzle by looking for the genetic fingerprints of fat toxicity within the lungs of people with COPD. They began by gathering vast amounts of genetic data from public databases, comparing the lung tissue and blood of healthy individuals against those with the disease. They focused specifically on a list of genes known to be involved in fat toxicity. By cross-referencing this list with the genes that were behaving differently in COPD patients, the researchers narrowed down thousands of possibilities to a small group of twenty-eight genes that seemed most relevant.

To find the most important players among these twenty-eight, the team used powerful computer algorithms designed to spot patterns. These tools helped them identify two specific genes that stood out as the most reliable indicators of the disease. One gene, called APRT, was found to be significantly less active in patients with COPD compared to healthy people. The other, known as S100A8, was much more active. To ensure these findings were not just a fluke of the computer data, the researchers tested them in a real-world setting. They collected blood samples from ten patients at their hospital—five with COPD and five without—and measured the levels of these genes directly. The results confirmed the computer predictions, showing that APRT expression was down-regulated while S100A8 exhibited significantly higher expression in COPD samples.

The researchers then used these two genes to build a predictive model, a tool that could estimate a person's risk of having the disease based on their genetic profile. When they tested this model, it proved highly accurate at distinguishing between healthy individuals and those with COPD. Beyond just diagnosis, the study explored what these genes were actually doing inside the body. The analysis showed that both genes were closely linked to a specific biological pathway known as focal adhesion, which helps cells stick to their surroundings and communicate with one another. The study also revealed that these genes were strongly connected to the behavior of neutrophils, a type of white blood cell that rushes to sites of infection or injury. In COPD patients, these cells are often found in higher numbers, and the study suggested that the high levels of S100A8 might be encouraging this accumulation, while low levels of APRT might fail to stop it.

To understand which cells in the lung were driving this process, the team turned to a high-resolution technique called single-cell RNA sequencing. This method allows scientists to look at the genetic activity of individual cells rather than just the average of a whole tissue sample. This detailed view revealed that macrophages, a type of immune cell that acts as a cleaner and defender in the lungs, were the primary location where these genetic changes were happening. The researchers tracked how these macrophages changed over time and found that the levels of the two key genes fluctuated in a specific pattern as the cells matured. This suggests that the fat toxicity process is not a static event but a dynamic one, evolving as the immune cells change their role in the diseased lung.

The study also looked ahead to potential treatments. By analyzing the genetic targets of these two genes, the researchers predicted interactions with several existing drugs that might influence them. For instance, they found that certain medications could potentially target the S100A8 gene, while others might influence APRT. While these drugs were not tested in this specific study, the identification of these targets opens a new door for future therapies. The researchers concluded that APRT and S100A8 are not just markers for the disease but likely play a role in how fat toxicity damages the lungs, though the exact mechanism of action needs to be verified and clarified through future experimental studies. By understanding this mechanism, doctors may one day be able to develop treatments that specifically block the harmful effects of fat buildup, offering hope for a more targeted approach to managing a disease that currently has no cure.